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Abstract: Breast cancer in young women is relatively rare compared to breast cancer occurring 
in older women. Younger women diagnosed with breast cancer also tend to have a more aggressive 
biology and consequently a poorer prognosis than older women. In addition, they face unique 
challenges such as diminished fertility from premature ovarian failure, extended survivorship 
periods and its attendant problems, and the psychosocial impact of diagnosis, while still raising 
families. It is therefore imperative to recognize the unique issues that younger women face, 
and plan management in a multidisciplinary fashion to optimize clinical outcomes. This paper 
discusses the challenges of breast cancer management for young women, as well as specific 
issues to consider in diagnosis, treatment, and follow-up of such patients.
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Introduction
Early-onset breast cancer is relatively rare; however, it represents the commonest cause 
of cancer in women under age the of 40.1 In the US, approximately 33,000 women under 
the age of 45 years are diagnosed with breast cancer every year, and it is the leading 
cause of cancer-related deaths in this age group.2 Compared to older women with 
breast cancer, younger women tend to have a more aggressive biology and a poorer 
prognosis (Table 1). Younger women with breast cancer also face unique challenges 
such as premature ovarian failure, psychosocial issues with ongoing careers, and 
raising young families, as well as extended survivorship periods and its attendant 
complications as summarized in Figure 1. It is therefore imperative to recognize the 
unique issues that younger women face and plan management in a multidisciplinary 
fashion to optimize clinical outcomes.
Breast cancer screening
Screening for breast cancer should begin at age 40 for average-risk women.3 This 
includes annual mammography and clinical breast examination (CBE). Breast self-
examination (BSE) is an additional option. For average-risk women under age 40, 
screening consists of CBE every 3 years with optional BSE; routine use of imaging 
is not recommended. Although no studies have documented improved breast cancer-
related outcomes with BSE, given that routine imaging is not warranted, most malig-
nancies in women under 40 will be detected by patients.4 Even for young women who 
do undergo annual mammography, cancers that develop are more likely to present as 
interval cancers.5–7 For this reason as well, CBE and BSE remain important screening 
modalities for young women. Increased breast density seen in younger women lowers 





the sensitivity of mammography.8 Despite this, mammogra-
phy is still an important screening tool. The incorporation 
of tomosynthesis, or three-dimensional mammography, will 
likely improve the sensitivity and specificity of mammogra-
phy in women with dense breast tissue.9
Diagnostic evaluation of young 
women with breast complaints
Women, regardless of age, who present with symptoms, 
require diagnostic evaluation and a CBE. Because younger 
women do not undergo routine screening mammography, 
most will present with symptomatic and higher stage 
breast cancer10,11 versus women diagnosed with a screening 
study. Young age and symptomatic presentation are both 
associated with delay in diagnosis and worse outcomes.10–12 
The imaging modality selected for the diagnostic workup 
depends on the patient’s age and presenting symptoms.13–16 
Masses should be evaluated by ultrasound with or without 
mammography, depending on the patient’s age, the clinical 
suspicion, and the nature of the mass. Pathologic nipple 
discharge concerning for ductal carcinoma in situ may 
mandate mammography even in younger women to evalu-
ate for calcifications. Magnetic resonance (MR) is typically 
not indicated for evaluation of mammographic or ultrasound 
abnormalities; suspicious findings on conventional imaging 
or examination require standard evaluation, including biopsy, 
even in the setting of a negative MR. Negative imaging of 
any type does not negate the possibility of malignancy, and 
therefore even in the setting of normal imaging, suspicious 
palpable findings require biopsy for definitive diagnosis.
Genetic predisposition
First-degree relatives of women with breast cancer have 
nearly a twofold increased breast cancer risk compared to the 
general population, and this risk is much higher when the rel-
ative is diagnosed at a young age.17,18 Large twin studies have 
demonstrated nearly one-third of all breast cancer is attributed 
to hereditary factors.19,20 However, the susceptibility genes 
Table 1 Breast cancer features in younger patients
incidence More common in older women. 4.5% incidence 
in women age ,40138
Presentation More advanced in younger women, more 
diagnostic delays10,11
Biology High frequency of HR-negative disease29
Genetics As younger women are more likely to have 
inherited susceptibility, genetic testing is 
recommended for all patients #40 years
Prognosis inferior outcome in younger patients45,57,58
Unique considerations Premature ovarian failure, reduced fertility, 
increased social stressors from raising young 
children and active workforce participation, 
prolonged survivorship period, bone loss



















Figure 1 Breast cancer diagnosis and treatment effects on young women.




Breast cancer in young women
identified to date account for only 20%–30% of the excess 
familial risk.21,22 Consequently, the genetic etiology for the 
majority of families with an increased familial breast cancer 
risk remains unknown.
Young age at diagnosis is a feature of hereditary disease, 
and it is currently recommended that all women diagnosed 
with breast cancer less than 40 years of age be referred for 
genetics assessment. A higher proportion of young women 
with breast cancer have germline mutations, compared to 
their older counterparts, with most studies evaluating the 
prevalence of BRCA1, BRCA2, and TP53 mutations.23–25 
Furthermore, a greater proportion of young women, espe-
cially black women, have triple-negative disease, and among 
these women there is also an increased frequency of germline 
mutations, notably in BRCA1, BRCA2, and PALB2 genes.26 
Identification of germline mutations has the potential to 
impact a woman’s medical care, and to be informative for 
at-risk family members.
Multiple gene panels, with concurrent analysis of genes 
with varied levels of breast cancer risk, are now commonly 
used in clinical practice. Maxwell et al27 evaluated the use 
of a 22-gene panel among a cohort of young women with 
breast cancer, classifying the results into clinically actionable 
and unclear actionability, based on the available data of the 
risks associated with each gene. Only 2.5% of this cohort of 
278 patients was identified with clinically actionable gene 
variants compared to 8.6% of patients with variants for which 
clinical data are deficient.27 The current lack of clinical valid-
ity for many genes makes translating clinical genetic testing 
results into improved patient care difficult, with the potential 
for overtreatment. Some investigators have advocated that 
genetic testing for breast cancer risk should only be offered 
after the clinical validity is established for the genes to be 
analyzed.28 Until additional cancer susceptibility genes are 
discovered and clinical validation of recently discovered 
genes is performed, clinicians will need to continue to rely on 
the family cancer history to help guide medical care for the 
majority of young women diagnosed with breast cancer.
Biology of early-onset breast cancer
Differences in pathologic characteristics between younger and 
older women with breast cancers have been observed in mul-
tiple studies. The Prospective study of Outcomes in Sporadic 
and Hereditary breast cancer is the largest to investigate fac-
tors affecting breast cancer prognosis in patients #40 years; 
however, there is no comparison to older women due to the 
observational nature of the study.29 Although only 30% of 
the patients had screen-detected cancers, 50% of the patients 
in this multicenter study presented with nodal involvement. 
One-third of them were hormone receptor (HR) negative, 
20% had triple-negative breast cancer, and almost 60% had 
poorly differentiated tumors. In addition, although majority 
of patients received chemotherapy in addition to endocrine 
therapy, 10% of those with HR-positive breast cancer devel-
oped a late relapse between years 5 and 8. At a median 
follow-up of 5 years, the overall survival was 82%, with the 
majority of deaths due to breast cancer. Another large study 
using the California Cancer Registry also found that 20% of 
adolescents and young adults with breast cancer had triple-
negative disease and 54% had high-grade tumors.30 Numerous 
other studies have also suggested more biologically aggressive 
cancers in younger women.10,31–37
Gene expression profiling has subdivided triple-negative-
breast cancer (TNBC) patients into clinically relevant 
subtypes now being used to design clinical trials.38 
A comprehensive study on TNBC samples revealed several 
biomarkers, including TP53, PIK3CA, AKT1, PTEN, and 
HER2 mutations that may be therapeutically relevant in 
the future.39 Clinical trials investigating agents targeted at 
such aberrations are underway. For example, a recent open-
label Phase II trial investigating enzalutamide, an androgen 
receptor (AR) antagonist, in AR-positive advanced TNBC 
patients, reported a 16-week clinical benefit rate of 35%.40 
TNBC cases that were strongly AR-positive exhibited lower 
proliferation rates than those that were not AR-positive.39 
These AR-positive tumors tend to be rich in genes regulated 
by the hormonal pathway.
TNBC is an immunogenic form of breast cancer due to 
the frequency of mutations causing neoantigens, and the asso-
ciation between high rates of tumor infiltrating lymphocytes 
and improved response to chemotherapy and survival seen 
in that subset of breast cancer.41,42 Novel immune checkpoint 
inhibitors, such as the PDL1 and PD1 inhibitors, appear to 
have activity in TNBC patients as well. Two studies utilizing 
these agents in the advanced TNBC setting reported durable 
clinical benefits in patients with PDL1-positive TNBC.43,44 
Thus, new predictive markers in TNBC may prove to be 
therapeutically relevant in the future.
Several groups have also found gene expression profile 
differences between breast cancers occurring in younger ver-
sus older women. In the largest study evaluating age-related 
biological differences in breast cancer, Azim et al45 found that 
genes enriched in processes related to immature mammary 
cell populations (RANKL, c-kit, BRCA1, mammary stem 
cells, and luminal progenitors cells) and growth factor signal-
ing (MAPK, PI3K) were predominant in younger women.





Analysis of clinically annotated microarray data 
from 784 breast cancer patients also revealed that young 
women #45 years had lower mRNA expression of ERα, 
ERβ, and PR, but higher expression of HER2 and EGFR as 
opposed to women $65 years.46 In women ,40 years, gene 
expression profiling further showed lower expression of ERα 
and ERβ compared with women 40–50 years. In addition, 
gene sets unique to younger women included those related 
to biologically relevant and potentially actionable processes 
such as immune function, mTOR/rapamycin pathway, 
hypoxia, BRCA1, stem cells, apoptosis, histone deacetylase, 
and multiple oncogenic signaling pathways.
Differences in biology in young women also differ 
by race. In a large Surveillance, Epidemiology, and End 
Result (SEER) study involving over 126,000 women 
aged #49 years with breast cancer, we have previously 
reported that a higher proportion of blacks versus whites 
developed breast cancer under age 40. A higher proportion 
of blacks also presented with HR negative, more advanced 
stage, and higher grade tumors.47 In the Carolina Breast 
Cancer Study, the prevalence of basal-like breast cancer was 
highest (39%) among black premenopausal women compared 
with other groups of patients (14%–16%).48 This has also 
been observed in other studies in the US.49,50
Prognosis
A recent study showed an increase in the incidence of young 
women aged 25–39 years diagnosed with metastatic breast 
cancer from 1.53 to 2.90 per 100,000 from 1976 to 2009.51 
Several reasons such as stage migration, improved surveil-
lance, and population-based changes in breast cancer risk 
factors may be implicated. This increase is particularly con-
cerning as young age is an independent adverse factor for 
poor prognosis among women with breast cancer.1,52–56 The 
clinical outcome is worsened for very young women under 
age 35, with the hazard of death increasing by every 1 year 
decrease in age.57 It is also apparent that the effect of age on 
outcome is modified by breast cancer subtype. A study by 
Sheridan et al58 showed that within the HR-positive subtype, 
younger age carried a worse prognosis than older age. This has 
also been confirmed in Azim et al’s45 study, where they found 
an inferior relapse-free survival with young age in the HR-
positive/HER2-negative subtype in a subgroup analysis.
Treatment
Locoregional treatment – surgery
Young women with breast cancer have similar surgical 
options as older women. These include breast conserva-
tion therapy (BCT) (partial mastectomy with radiation) or 
mastectomy. Although young age at diagnosis is associated 
with a higher risk of local recurrence and more aggressive 
phenotypes, data suggest no survival gains with mastectomy 
compared to BCT, and there does not appear to be a sur-
vival advantage with contralateral prophylactic mastectomy 
either.59–63 Therefore, young age alone is not a contraindica-
tion to BCT. Despite this, bilateral mastectomies are on the 
rise in women of all ages.61–63 This is likely due to patient 
and physician perception of improved outcomes and due to 
improved reconstruction techniques and cosmesis. Immedi-
ate and immediate-delayed reconstruction are now preferred, 
and many women are candidates for nipple sparing proce-
dures with immediate or immediate-delayed reconstruction. 
Nipple sparing procedures are increasingly being offered as 
data supports the oncologic safety, and these procedures are 
associated with better self-image.64,65
Locoregional treatment – radiotherapy
After partial mastectomy, adjuvant whole breast radiation 
has been shown to reduce the risk of ipsilateral breast tumor 
recurrence, as well as improve breast cancer survival.66,67 
Adjuvant radiation is especially important for young women 
in this setting, as their absolute risk of local recurrence is 
higher than for older women, and as a result, younger women 
have a greater absolute benefit from adjuvant radiation.67
For young women with early-stage breast cancer, there are 
important considerations with regards to treatment volume. 
Accelerated partial breast irradiation (APBI) may not be an 
appropriate option for young women. Although results from 
the NSABP B-39 trial,68 comparing whole and partial breast 
radiation, are pending, there are several published consensus 
statements describing APBI selection criteria. All include a 
minimum patient age in their criteria, ranging from 45 to 
60 years as the suggested minimum age.69–71 This is based 
on the existing published literature on APBI which primar-
ily includes women over 50, the concern for increased risk 
of multifocal and multicentric disease in younger women, 
and the known higher local recurrence rates seen in young 
women who receive whole breast radiation. NSABP B-39 
trial included women over 18 years old, and we await the 
results from this trial.
Other considerations with regards to dose and fraction-
ation include the use of boost and hypofractionation. In the 
European Organization for Research and Treatment of Cancer 
trial, use of boost reduced the 20-year cumulative incidence 
of ipsilateral breast tumor recurrence from 16.4% to 12.0% 
(hazard ratio: 0.65, P,0.0001).72 The benefit of a boost 
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was found to be greatest for young women. The absolute 
risk reduction was 4.4% in the entire cohort, and 11.6% for 
women under 40. Hypofractionated whole-breast schedules 
have been found to be as effective as standard fractionation 
for certain populations. However, majority of these data 
were obtained in women over 50 years old, and therefore 
the American Society for Radiation Oncology guidelines on 
fractionation support the use of hypofractionation only for 
women over 50, who also meet the other specified criteria.73 
Until further evidence is available for younger women, the 
standard of care for these women includes delivery of whole-
breast radiation with standard fractionation.
For women with locally advanced breast cancer, random-
ized trials have demonstrated a locoregional recurrence and 
survival benefit to postmastectomy radiation for women 
with large primary tumors .5 cm, invasion of the skin or 
chest wall, or lymph node involvement.74–76 Retrospective 
analysis of 107 stage II or III patients aged #35 years treated 
with or without adjuvant radiation following mastectomy 
showed that patients who received postmastectomy radia-
tion compared with those who did not had a better 5-year 
local control and overall survival rates.77 Since young age 
and/or premenopausal status are risk factors for locoregional 
recurrence after mastectomy, some young women with node 
negative disease may benefit from postmastectomy radiation 
if they have additional risk factors.78–80
For most breast cancer scenarios, young women have a 
higher risk of local and regional recurrence, and therefore 
derive an even greater absolute benefit from adjuvant radia-
tion than older women. Given their young age and potential 
for long-term survival, special care must be taken during 
radiation treatment planning to minimize radiation exposure 
to adjacent organs in order to reduce the risk of late effects 
and secondary malignancies.
Systemic treatment – endocrine
The Early Breast Cancer Trialists’ Collaborative Group’s 
(EBCTCG) meta-analyses demonstrated that 5 years of 
adjuvant tamoxifen improved the annual breast cancer death 
rate by one-third and recurrence risk by 50% for all women 
with HR-positive cancers irrespective of age.81 However, 
approximately 10% of those with HR-positive cancers will 
develop a late relapse beyond year 5; therefore, there has 
been interest in extending adjuvant endocrine therapy to 
prevent later relapses. In the Adjuvant Tamoxifen: Longer 
Against Shorter trial, women with early stage breast cancer 
were randomly assigned to continue tamoxifen to 10 years 
or stop at 5.82 Allocation to 10 years was associated with 
reductions in the risk of recurrence, improvements in breast 
cancer specific survival, and overall survival. Similarly, in 
the UK adjuvant Tamoxifen-To offer more? trial, 10 years 
of adjuvant tamoxifen reduced late breast cancer recurrences 
and mortality among women with HR-positive cancers.83 
The group that continued tamoxifen to year 10 had further 
reductions in recurrence, from year 7 onward, as well as 
breast cancer mortality after year 10. Based on these and 
other studies, the American Society for Clinical Oncology 
clinical practice guideline now recommends treatment with 
adjuvant tamoxifen for 10 years in women with stage I–III 
HR-positive cancers. While these results were not restricted 
to young women, in clinical practice, young patients who 
are believed to have a worse prognosis are generally being 
considered for 10 rather than 5 years of tamoxifen.
An alternative form of endocrine manipulation involves 
ovarian suppression (OS). Although, the prognosis for pre-
menopausal women who have chemotherapy-induced amen-
orrhea (CIA) is better than for those who do not have CIA, the 
prognostic value of therapeutic OS remains unclear.84–86 The 
Suppression of Ovarian Function (SOFT) trial was designed 
to determine the utility of dual endocrine blockade by add-
ing OS to tamoxifen and also to determine the benefit of an 
aromatase inhibitor with OS for premenopausal patients.87 
Premenopausal women were assigned to either 5 years of 
tamoxifen, tamoxifen plus OS, or exemestane plus OS. At 
5 years, 90.9% of those who received exemestane with OS 
were free from breast cancer, versus 88.4% in the tamoxifen 
plus OS arm, versus 86.4% in the tamoxifen alone group. In 
the subgroup of women younger than 35 years, the rate of 
freedom from breast cancer at 5 years was 83.4% for those 
assigned to exemestane plus OS, 78.9% for those assigned 
to tamoxifen plus OS, and 67.7% for patients assigned to 
tamoxifen alone. Similarly, the Tamoxifen and Exemestane 
Trial (TEXT) was designed to compare exemestane plus OS 
versus tamoxifen plus OS also in premenopausal women.88 
In the combined analysis of both SOFT and TEXT trials, 
the 5-year rate of freedom from breast cancer was 92.8% 
in those receiving exemestane plus OS, versus 88.8% for 
those assigned to receive tamoxifen plus OS. The symptom 
burden of OS with either tamoxifen or exemestane is higher 
than tamoxifen alone and different depending on what drug 
is given in combination with OS. Patients who receive 
tamoxifen have more vasomotor symptoms, while those who 
receive exemestane have more arthralgia, sexual dysfunction, 
and vaginal dryness.89 These side effects need to be discussed 
with individual patients prior to electing treatment. Results 
from these studies show that even in premenopausal women 





with early stage breast cancer, the outcomes in those with HR-
positive cancers is very good in general; however, there is still 
a need to define who merits more aggressive therapy. In addi-
tion, further tools and research are needed on compliance, 
management of menopausal symptoms, bone loss, cognitive 
problems, and sexual dysfunction, and careful monitoring of 
late side effects such as secondary malignancies.
Systemic treatment – chemotherapy
The preferred chemotherapy regimens remain the same for 
all patients with early stage breast cancer irrespective of 
age. In general, for most high-risk breast cancer patients, 
combination regimens including anthracyclines and taxanes 
are employed. The EBCTCG meta-analyses, evaluated the 
benefits of adjuvant polychemotherapy on outcomes in 
younger versus older women.81 Anthracycline-based che-
motherapy combinations had a larger impact in reducing 
the annual breast cancer death rate for women younger than 
50 years (38% reduction) versus 20% for those aged 50–69 
years. In addition, there was also a threefold age-related 
benefit for polychemotherapy versus no chemotherapy for 
women ,50 years versus women 50–69 years with larger 
benefits for recurrences than mortality. The 5-year improve-
ments from chemotherapy were approximately twofold for 
HR-negative versus HR-positive cancers, but the 15-year 
improvements were less dependent on HR status, likely due to 
differences in timing of recurrences with HR-negative versus 
HR-positive cancers. Preferred National Comprehensive Can-
cer Network (NCCN) guidelines for adjuvant chemotherapy 
for high-risk HR-breast cancer patients include several regi-
mens such as doxorubicin plus cyclophosphamide followed 
by paclitaxel or docetaxel plus cyclophosphamide.
Systemic treatment – biologic therapy
Patients who have HER2+ breast cancer receive trastuzumab 
as part of their (neo)adjuvant systemic treatment based on 
improvements in overall survival seen in large randomized 
trials.90–93 Young patients also derive similar benefits from 
adjuvant trastuzumab as older patients.12 Pertuzumab is a 
humanized monoclonal antibody directed at HER2 and is 
approved in combination with trastuzumab and chemother-
apy for treatment of HER2+ breast cancers in the neoadjuvant 
and advanced settings based on several studies.94–96
Unique considerations
Fertility preservation
Among the unique concerns for young women with breast 
cancer are treatment-induced ovarian failure and infertility. 
The risk of infertility varies according to age, reproductive 
reserve, chemotherapy agent, duration of treatment, and dose 
administered.97 Alkylating agents are among those with the 
highest gonadotoxic properties.98 The true rates of infertility 
after breast cancer treatments have been difficult to ascer-
tain as there is no consensus on what constitutes infertility. 
Different surrogates used in different studies include amen-
orrhea, estradiol, anti-Mullerian hormone, inhibin B, and 
follicle count.99,100
Young women who are desirous of future childbearing 
should be properly counseled by an oncofertility specialist 
on options for fertility preservation prior to chemotherapy. 
Existing reproductive options include embryo and oocyte 
cryopreservation, cryopreservation of ovarian tissue, or 
OS with luteinizing hormone releasing hormone (LHRH) 
agonists.101–103 The POEMS study randomized 257 pre-
menopausal women with HR-negative breast cancer to 
receive standard chemotherapy with or without goserelin to 
determine if goserelin reduced ovarian failure.104 The ovarian 
failure rate was 8% in the intervention group versus 22% in 
the chemotherapy group. In addition, 22 patients in the gos-
erelin group achieved at least 1 pregnancy versus 12 in the 
standard group, although more women in the goserelin group 
attempted pregnancy. While these data are encouraging, the 
use in those with HR-positive cancer is cautioned, as this 
study only included those with HR-negative cancer. Although 
less of an issue with LHRH agonists that are administered 
during chemotherapy, practical barriers limiting fertility 
preservation are cost, insurance, absence of a male partner, 
and chemotherapy timing issues.
Retrospective studies have suggested no worsening 
of breast cancer outcomes in patients who become 
pregnant.105–108 POSITIVE (Pregnancy Outcome and Safety 
of Interrupting Therapy for women with endocrine respon-
sIVE Breast Cancer) is an ongoing trial, designed to evaluate 
the safety and outcomes of women with HR-positive cancers 
who interrupt endocrine therapy for childbearing. This trial 
seeks to enroll women under age 42 who have received 
18–30 months of endocrine therapy and who then stop endo-
crine therapy temporarily to attempt pregnancy.109 Guidelines 
also recommend avoiding pregnancy within 6 months of 
systemic therapy completion, due to teratogenicity.110,111
Pregnancy-associated breast cancer
The incidence of pregnancy at the time of breast cancer diag-
nosis is approximately 1.5%, and breast cancer is the most 
common pregnancy-associated malignancy in women.112–114 
A confirmed diagnosis of malignancy should prompt 
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diagnostic mammography in addition to ultrasound with 
uterine shielding.115 Fine needle aspiration may be difficult 
to interpret in the setting of pregnancy-related proliferative 
changes;116 core biopsy is preferred. The pathologist should 
be alerted to the patient’s gravid state. Staging should be 
directed by signs and symptoms and by clinical stage as for 
the nonpregnant patient. Computed tomography, plain X-ray, 
and nuclear medicine studies expose the fetus to radiation, 
and so risks and benefits of this exposure need to be weighed. 
Nuclear medicine studies are typically avoided due to a lack 
of safety data, and breast MR, which requires gadolinium 
contrast, is not safe during pregnancy.117,118
Surgery is often the safest mode of treatment during early 
pregnancy as endocrine and cytotoxic therapies are contrain-
dicated during the first trimester.119 For patients who undergo 
surgery early in pregnancy and who do not need adjuvant che-
motherapy, radiation may be delayed many months although 
studies suggest worse outcomes with such delays.120 Fetal 
radiation exposure is associated with birth defects, mental 
retardation, childhood malignancy, and other complications, 
and as the fetus grows its proximity to the breast increases, the 
potential for fetal radiation exposure increases.119,121 Therefore, 
radiation is contraindicated in the third trimester. Clinically 
node-negative women undergo axillary staging with a sentinel 
lymph node biopsy. Traditionally, radioisotope was avoided due 
to the risk of radiation exposure to the fetus. More recent data 
suggest that the dose to the fetus is small, and available data 
suggest no negative impact on pregnancy outcomes with the 
use of radioisotope.122,123 This method of sentinel node mapping 
may be preferred due to continued concerns about teratogenic-
ity or maternal anaphylaxis with methylene blue and isosulfan 
blue dye, respectively, both of which are Pregnancy Class C 
drugs. A small series, however, has not demonstrated negative 
pregnancy outcomes with the use of blue dyes.123 The potential 
risks and benefits of the sentinel node procedure need to be 
discussed with patients preoperatively.
Fetal malformations are seen with first trimester exposure 
to chemotherapy.124 Anthracycline-based regimens have the 
most available data and can be given during the second and 
third trimesters.125–127 Chemotherapy should be withheld 
ideally at least 3 weeks before confinement to avoid cytope-
nias at the time of delivery. Other systemic therapies such 
as endocrine therapy and trastuzumab are contraindicated 
during pregnancy.128
Bone health
Young women with breast cancer are at higher risk of long-
term side effects from cancer treatments and survivorship 
due to the longer life expectancy. One particular area which 
has received a lot of recent attention is bone health. Although 
fragility fractures are more common in women over 50 years, 
several factors lead to bone compromise in younger women 
treated for breast cancer. Androgens and estrogens are regu-
lators of bone growth, and consequently, estrogen deficiency 
is a key determinant in bone loss. Cancer treatments with 
chemotherapy can lead to estrogen deficiency via gonadal 
dysfunction, and also impair bone health via direct effects 
on bone metabolism or systemic steroids commonly used 
as supportive medications during chemotherapy. Radiation 
can impair bone integrity in the treated radiation field. 
Hormonal treatment designed to induce hypogonadism also 
leads to accelerated bone loss. In premenopausal women 
receiving endocrine therapy for breast cancer, changes in 
bone mineral density have been observed with tamoxifen, 
ovarian suppression, tamoxifen or aromatase inhibitors with 
ovarian suppression, and oophorectomy.129–131 Thresholds for 
pharmacologic intervention with bisphosphonates or RANK 
ligand inhibitors include a history of osteoporosis, fragility 
fractures, and osteopenia with additional risk factors. Several 
studies have confirmed that antiresorptive therapies maintain 
or increase bone mineral density in women or men treated 
with endocrine therapy.129,132–137 While this is encouraging, 
it remains unclear what impact these treatments have on the 


















































Figure 2 essential components of a survivorship plan.






Young patients with breast cancer face unique manage-
ment challenges that are best addressed in a multidisci-
plinary setting. Currently, treatment recommendations 
are made on tumor characteristics and not solely on age. 
Close attention to long-term side effects with optimal 
supportive care should be considered. A survivorship 
care plan involving a multidisciplinary team is essential 
for young patients (Figure 2). Younger patients are also 
underrepresented in clinical trials and should be encour-
aged to participate for a better understanding of early-onset 
breast cancer.
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